HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Obesity · Neuromodulation Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Obesity · Neuromodulation Competitive Landscape

20 findings · 27 signals · 7 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

Moderate Confidence · 72%

Evidence

47 items

Sources

4

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Obesity · Neuromodulation synthesizes 20 Competitiva findings across 27 active signals. 2 high-pressure competitive threats identified. 7 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Pfizer — Foundayo

    Pfizer is a direct competitive threat because it is already approved in Obesity · GLP-1 Agonists (Foundayo) and could narrow Lilly's development lead.

    View detail
  2. competitive

    Pfizer — Tirzepatide

    Pfizer is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    View detail
  3. competitive

    Roche — Tirzepatide

    Roche is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    View detail
  4. competitive

    Roche — Tirzepatide

    Roche is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    View detail
  5. competitive

    Lilly — Pipeline activity

    Lilly is an emerging emerging competitor with Phase III activity on Pipeline activity in Obesity · Peptide Therapy; while behind Roche (Phase II), accelerated readouts could compress Roche's strategic window.

    View detail
  6. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    View detail
  7. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    View detail
  8. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    View detail
  9. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    View detail
  10. competitive

    Pfizer — Pipeline activity

    Pfizer is a direct competitive threat because it has a Phase III program in Obesity · Triple Agonist (Pipeline activity) and could narrow Lilly's development lead.

    View detail
  11. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Oral GLP-1 receptor agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    View detail
  12. competitive

    Roche — Pipeline activity

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Oral GLP-1 receptor agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 2 high-pressure competitive programs for portfolio displacement risk. Cross-reference 7 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Pfizer — Foundayo

    75%

    Pfizer is a direct competitive threat because it is already approved in Obesity · GLP-1 Agonists (Foundayo) and could narrow Lilly's development lead.

    Source: Pfizer

    View evidence

  • Pfizer — Tirzepatide

    80%

    Pfizer is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    Source: Pfizer

    View evidence

  • Roche — Tirzepatide

    80%

    Roche is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Roche — Tirzepatide

    80%

    Roche is a direct competitive threat because it has a development-stage program in Obesity · GLP-1 Agonist (Tirzepatide) and could narrow Lilly's development lead.

    Source: Roche

    View evidence

  • Lilly — Pipeline activity

    72%

    Lilly is an emerging emerging competitor with Phase III activity on Pipeline activity in Obesity · Peptide Therapy; while behind Roche (Phase II), accelerated readouts could compress Roche's strategic window.

    Source: Lilly

    View evidence

  • Roche — Pipeline activity

    65%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    65%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    69%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    Source: Humanexa Signals

    View evidence

  • Roche — Pipeline activity

    69%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Triple Agonist; while behind Lilly (Phase III), accelerated readouts could compress Lilly's strategic window.

    Source: Humanexa Signals

    View evidence

  • Pfizer — Pipeline activity

    69%

    Pfizer is a direct competitive threat because it has a Phase III program in Obesity · Triple Agonist (Pipeline activity) and could narrow Lilly's development lead.

    Source: Humanexa Signals

    View evidence

  • Roche — Pipeline activity

    76%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Oral GLP-1 receptor agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Roche — Pipeline activity

    76%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Oral GLP-1 receptor agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Roche

    View evidence

  • Pfizer — Pipeline activity

    76%

    Pfizer is a direct competitive threat because it has a development-stage program in Obesity · Oral GLP-1 receptor agonist (Pipeline activity) and could narrow Lilly's development lead.

    Source: Pfizer

    View evidence

  • Roche — Pipeline activity

    82%

    Roche is an emerging emerging competitor with Phase II activity on Pipeline activity in Obesity · Oral GLP-1 receptor agonist; while behind Lilly (development-stage), accelerated readouts could compress Lilly's strategic window.

    Source: Humanexa Signals

    View evidence

  • Pfizer — Pipeline activity

    95%

    Pfizer is a direct competitive threat because it has a development-stage program in Obesity · Oral GLP-1 receptor agonist (Pipeline activity) and could narrow Lilly's development lead.

    Source: Humanexa Signals

    View evidence

  • Roche — Berobenatide

    54%

    Roche is a direct competitive threat because it has a Phase II program in Obesity · GLP-1 Receptor Agonist (Berobenatide) and could narrow Pfizer's development lead — particularly against Berobenatide.

    Source: Roche

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Allurion Gastric Balloon Safety Update: Risks of Obstruction and Perforation

    Safety Signal

  • FDA Approves Supplemental Application for Wegovy (Semaglutide)

    Regulatory Approval

  • Lilly's Obesity Medicines Accessible to Medicare Part D Patients via New Program

    Regulatory Approval

  • Semaglutide tablet approved in the UK for weight loss

    Regulatory Approval

  • CVS Caremark to cover Foundayo and Zepbound, enhancing access for obesity treatment

    Competitive Move

  • Foundayo shows significant weight reduction in older adults with obesity in new analysis

    Trial Update

  • Lilly's retatrutide shows significant weight loss in Phase 3 obesity trial

    Trial Update

  • Roche Advances Obesity Portfolio with Promising Phase II Data on Enicepatide and Petrelintide

    Trial Update

Insights

  • Regulatory Risks and Market Dynamics for Allurion Gastric Balloon Safety Concerns

    Obesity · Medical Device

  • Lilly's Medicare GLP-1 Bridge Program Enhances Competitive Position in Obesity Market

    Obesity · GLP-1 Agonists

  • Semaglutide Tablet Approval Enhances Competitive Position in Obesity Market

    Obesity · GLP-1

  • Eli Lilly Gains Competitive Edge in Obesity Market with Enhanced Access Strategies

    Obesity · Pharmacotherapy

  • Competitive Dynamics Intensify in Obesity Treatment Market with New Efficacy Data

    Obesity · Oral GLP-1 receptor agonist

  • Emerging Competitive Landscape in Obesity Treatments: Key Trials and Strategic Implications

    Obesity · GLP-1 Receptor Agonist

  • Roche and Eli Lilly's Competitive Advances in Obesity Treatment Landscape

    Obesity · GLP-1/GIP Receptor Agonist and Amylin Analog

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Eli Lilly

    78 signals

  • Novo Nordisk

    9 signals

  • Biogen

    7 signals

  • Dr. Reddy's

    8 signals

  • Dr. Reddy's Labs

    4 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.